Evotec SE
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Evotec SE (EVO) is a life science company that pioneers drug discovery and development through integrated R&D solutions, AI-driven platforms, and advanced technologies for pharmaceutical and biotechnology partners worldwide. Founded in 1993 and headquartered in Hamburg, Germany, the company offers drug discovery services including target identification, hit identification, medicinal chemistry, ADME-Tox screening, in vitro and in vivo pharmacology, biomarker discovery, and data science analytics utilizing artificial intelligence and machine learning; preclinical development encompassing formulation science, process development, predictive safety, and investigational new drug enablement; biologics solutions via Just – Evotec Biologics featuring continuous manufacturing platforms like J.POD for protein therapeutics design, development, clinical supply, and commercial-scale production; and modalities spanning small molecules, biotherapeutics, cell therapies, and induced pluripotent stem cell-based disease modeling across therapeutic areas such as oncology, neurology, metabolic diseases, infectious diseases, immunology, and cardiovascular conditions. Evotec operates globally with facilities in Europe, the United States, and partnerships extending to Asia, serving top 20 pharma companies, over 800 biotechs, academic institutions, and venture capitalists through flexible models including standalone services, fully integrated programs, and long-term alliances with partners like Bristol Myers Squibb, Bayer, Sanofi, Novo Nordisk, Pfizer, and the CHDI Foundation. Recent developments include the extension of its neuroscience and targeted protein degradation collaboration with Bristol Myers Squibb yielding performance-based payments exceeding US$100 million in 2025; new multi-year research partnerships with Novo Nordisk for cell therapies and Pfizer for metabolic and infectious diseases research; advancement of multiple co-owned assets into phase II clinical trials; and a landmark November 2025 agreement with Sandoz for the sale of Just – Evotec Biologics EU in Toulouse plus an indefinite license to its continuous manufacturing technology, potentially generating over US$650 million in payments including US$350 million upfront, future milestones, and royalties on up to ten biosimilars targeting a US$90 billion market, enabling a sharper focus on asset-light biologics technology provision.
Company News
Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors
Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors
Brokerages Set Evotec AG (NASDAQ:EVO) PT at $3.00
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management
Evotec SE (EVO) Q2 2026 Earnings Call Transcript
Evotec Q2 Earnings Call Highlights
Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Evommune's Healthy Balance Sheet Buys Them Time For AD
Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics
Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
Evotec Reports Results of the Annual General Meeting 2026
Evotec Appoints Rui Wang as Head of Global In Silico and AI
Evotec SE Successfully Placed €116.1 Million Convertible Bonds
Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall
Evotec Receives Grants to Advance Tuberculosis Treatment